<DOC>
	<DOCNO>NCT01444898</DOCNO>
	<brief_summary>Prader-Willi Syndrome ( PWS ) one common genetic cause obesity . Obesity major source morbidity mortality population . It lead sleep apnea , cor pulmonale , diabetes mellitus , atherosclerosis . PWS distinct characteristic set apart forms obesity include insatiable appetite food-seeking behavior disruptive home school activity , cause severe social psychological turmoil within family . PWS also associate unique hormonal abnormality , notably hyperghrelinemia . Ghrelin gut hormone produce stomach stimulate food intake fast . It hypothesize extremely high ghrelin level patient PWS may cause contribute insatiable appetite . Exenatide , medication use treatment type 2 diabetes mellitus adult , appear suppress ghrelin level cause weight loss . It design mimic glucagon-like peptide 1 ( GLP-1 ) , incretin hormone stimulate insulin secretion delay gastric emptying , among effect . In present study , investigator investigate effect 6 month trial exenatide overweight adolescent PWS . The investigator quantify change weight body composition , well subjective measure appetite , concentration appetite-associated hormone . The investigator hypothesize exenatide improve weight , body composition , appetite , plasma ghrelin level treatment period .</brief_summary>
	<brief_title>Effects Exenatide Overweight Adolescents With Prader-Willi Syndrome</brief_title>
	<detailed_description>BACKGROUND : Prader-Willi syndrome ( PWS ) associate hyperphagia hyperghrelinemia major morbidity obesity without effective medical treatment target hyperphagia . Exenatide ( Byetta [ synthetic Exendin-4 ] ; AstraZeneca , Wilmington DE ) GLP-1 receptor agonist reduces appetite weight may effective treatment PWS . OBJECTIVE : The objective study determine effect 6-month trial exenatide appetite , weight gut hormone youth PWS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosis Prader Willi Syndrome confirm genetic testing ( DNA methylation FISH ) Ages 1320 year body mass index ( BMI ) &gt; 85th percentile age gender Is currently use previously use glucagonlike peptide1 ( GLP1 ) agonist History pancreatitis , renal failure History familial pancreatitis Amylase , lipase level &gt; 2.5 time upper limit normal time previous 2 year Creatinine clearance &lt; 30 mL/min Other syndromic diagnosis gastrointestinal ( GI ) renal illness 1 month prior enter study Inability take study drug Pregnancy Initiation growth hormone ( GH ) , estrogen , testosterone change &gt; 25 % dose/kg/day 6 month prior start study NonEnglish speaking</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prader-Willi Syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Weight</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Adolescents</keyword>
</DOC>